AR006202A1 - USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM - Google Patents

USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM

Info

Publication number
AR006202A1
AR006202A1 ARP970100986A ARP970100986A AR006202A1 AR 006202 A1 AR006202 A1 AR 006202A1 AR P970100986 A ARP970100986 A AR P970100986A AR P970100986 A ARP970100986 A AR P970100986A AR 006202 A1 AR006202 A1 AR 006202A1
Authority
AR
Argentina
Prior art keywords
prepare
treatment
ige
ige antagonist
compositions containing
Prior art date
Application number
ARP970100986A
Other languages
Spanish (es)
Original Assignee
Univ Johns Hopkins
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Genentech Inc filed Critical Univ Johns Hopkins
Publication of AR006202A1 publication Critical patent/AR006202A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Usos y composiciones de antagonista IgE para preparar un medicamento útil para el tratamiento de una enfermedad alérgica caracterizado por una cantidadefectiva de dicho antagonista IgE, que es administrado como: (a) una dosis de carga durante unperíodo de al menos alrededor de 14 días suficientes parareducir el nivel promedio de IgE libre en suero del paciente hasta un nivel no mayor de alrededor de 50ng/ml al final del período de carga; seguido por (b)una dosis de mantenimiento entrealre dedor de 8x10(5) hasta 2.4x10(3) mg/kg/semana del antagonista IgE para cada IU/ml línea de base IgE libre en elsuero del paciente.Uses and compositions of IgE antagonist to prepare a medicament useful for the treatment of an allergic disease characterized by a defective amount of said IgE antagonist, which is administered as: (a) a loading dose over a period of at least about 14 days sufficient to reduce the average level of free IgE in the patient's serum to a level no greater than about 50ng / ml at the end of the loading period; followed by (b) an interval maintenance dose of 8x10 (5) to 2.4x10 (3) mg / kg / week of the IgE antagonist for each IU / ml baseline free IgE in the patient's serum.

ARP970100986A 1996-03-12 1997-03-12 USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM AR006202A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US61422096A 1996-03-12 1996-03-12

Publications (1)

Publication Number Publication Date
AR006202A1 true AR006202A1 (en) 1999-08-11

Family

ID=24460327

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100986A AR006202A1 (en) 1996-03-12 1997-03-12 USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM

Country Status (8)

Country Link
EP (1) EP0904108A1 (en)
JP (1) JP2001505181A (en)
AR (1) AR006202A1 (en)
AU (1) AU726143B2 (en)
CA (1) CA2246427A1 (en)
IL (1) IL126113A0 (en)
WO (1) WO1997033616A1 (en)
ZA (1) ZA971607B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US7393529B2 (en) 1998-04-09 2008-07-01 Idexx Laboratories, Inc. Methods and compositions for inhibiting binding of IgE to a high affinity receptor
WO2001040264A2 (en) * 1999-12-06 2001-06-07 Panacea Pharmaceuticals, Llc. Peptide antigens
GB0016441D0 (en) 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US6787524B2 (en) 2000-09-22 2004-09-07 Tanox, Inc. CpG oligonucleotides and related compounds for enhancing ADCC induced by anti-IgE antibodies
WO2002089615A2 (en) * 2001-05-03 2002-11-14 Novartis Ag Anti-ige antibody to treat ocular allergies
GB201610198D0 (en) * 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN114028569B (en) * 2021-12-20 2023-04-28 中国医学科学院基础医学研究所 Use of immunoglobulin IgE for diagnosis and/or treatment of hypertension
CN114504644B (en) * 2021-12-24 2024-02-13 北京大学第一医院 Use of anti-IgE antibodies for the treatment of adenoid hypertrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5449760A (en) * 1987-12-31 1995-09-12 Tanox Biosystems, Inc. Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils
US4940715A (en) * 1988-05-17 1990-07-10 Kissei Pharmaceutical Co., Ltd. 5H-pyrazolo[4,3-A] quinolizin-5-one compounds exhibiting therapeutic activities
JP3156237B2 (en) * 1991-12-24 2001-04-16 雪印乳業株式会社 Anti-human IgE monoclonal antibody

Also Published As

Publication number Publication date
CA2246427A1 (en) 1997-09-18
IL126113A0 (en) 1999-05-09
EP0904108A1 (en) 1999-03-31
WO1997033616A1 (en) 1997-09-18
AU1987597A (en) 1997-10-01
AU726143B2 (en) 2000-11-02
JP2001505181A (en) 2001-04-17
ZA971607B (en) 1998-08-25

Similar Documents

Publication Publication Date Title
DE69027216D1 (en) TRANSMUCOSAL DOSAGE FORM
KR930702022A (en) Treatment or prevention of type 1 diabetes by oral administration of insulin
ES2171469T3 (en) COMPOSITION ADMINISTERED BY NASAL AND PREPARATION THAT CONTAINS IT.
PT88985A (en) Process for the preparation of nasal and ophthalmic pharmaceutical compositions containing azelastine
DE69230112D1 (en) ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE
ATE94393T1 (en) DOSE FORM FOR ORAL ADMINISTRATION OF HYPOGLYCAEMIC GLIPICIDE.
KR101900520B1 (en) A combination composition
ATE92762T1 (en) MEDICATION.
MX173567B (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL COMPOSITION AND PHARMACEUTICAL COMPOSITION TO IMPROVE THE SYMPTOMS OF HIV-INDUCED DISEASE OR REDUCE HIV TRANSCRIPTION AND PROLIFERATION
AU1935788A (en) A process for producing an administration and/or dosage form for medically active ingredients of drugs
DK0412554T3 (en) Sustained-release preparation for administration in the brain
ES2139842T3 (en) USE OF MELATONIN TO TREAT PATIENTS WHO SUFFER DRUG DEPENDENCE.
AR006202A1 (en) USES OF IGE ANTAGONIST TO PREPARE A USEFUL MEDICINAL PRODUCT FOR THE TREATMENT OF ALLERGIC DISEASES AND COMPOSITIONS CONTAINING THEM
RU95101385A (en) Products containing g-csf and tnf-binding protein
ES2119748T3 (en) PHARMACEUTICAL COMPOSITION CONTAINING A PHARMACEUTICALLY SOLUBLE IN WATER.
KR890006227A (en) Phenol-containing antitussive liquid composition
ES2115571T3 (en) USE OF PENTOSANA POLISULFATE FOR THE RESOLUTION OF SCARS IN CHRONIC PROGRESSIVE VASCULAR DISEASES.
JPH01261334A (en) Medical preparation containing angiotensine invertase inhibitor as effective component and production thereof
KR890004705A (en) Antiviral agents
JPS6360940A (en) Preventive or remedy for cataract
AR002727A1 (en) THE USE OF RIDOGREL FOR THE MANUFACTURE OF A MEDICATION USEFUL FOR THE TREATMENT OF DIGESTIVE INFLAMMATORY DISEASES, A PHARMACEUTICAL COMPOSITION INCLUDING RIDOGREL AND A PROCEDURE FOR PREPARING SUCH COMPOSITION.
ES2038847T3 (en) PROCESS FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION CONTAINING ZIDOVUDINE AND INOSIPLEX FOR THE TREATMENT OF AIDS AND RELATED SYNDROMES.
ES2211594T3 (en) MEDICATIONS CONTAINING PANTOTENIC ACID FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE ARTICULATIONS.
EP0402208B1 (en) Mixture of Vitamin A in physiological dosis and different active ingredients having therapeutic effect
AR062894A1 (en) FORMULATIONS FOR THERAPEUTIC ESTIMULATION HORMONE THERAPEUTIC ADMINISTRATION (THS)